Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

adweek.com - Mark Mwachiro - EXCLUSIVE: ESPN Spoofs Pharma Ads for March Madness
EXCLUSIVE: ESPN Spoofs Pharma Ads for March Madness
ADWEEK

From GLP-1s showing up at the Super Bowl to the Cialis ads of the world, TV viewers are getting increasingly familiar with pharmaceutical commercials appearing on their screens. ESPN is leveraging the familiarity of those ads in its latest March…

statnews.com - Ed Silverman - Pharmalittle: We're reading about pharma lobbying, a disappointing Novo clinical trial, and much more
Pharmalittle: We're reading about pharma lobbying, a disappointing Novo clinical trial, and much more
STAT

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned. Settling in may be a little more…

marketbeat.com - Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 28,053 Shares of Stock
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 28,053 Shares of Stock
MarketBeat

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 28,053 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $71.39, for a total transaction of $2,002,703.67.

marketbeat.com - Vanguard Group Inc. Acquires 347,074 Shares of BridgeBio Pharma, Inc. $BBIO
Vanguard Group Inc. Acquires 347,074 Shares of BridgeBio Pharma, Inc. $BBIO
MarketBeat

Vanguard Group Inc. lifted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 2.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 16,832,059 shares of the company's stock after purchasing…

bloomberg.com - Watch Trade Uncertainty Rattles Global Stock Markets | Open Interest 2/23/2026
Watch Trade Uncertainty Rattles Global Stock Markets | Open Interest 2/23/2026
Bloomberg

Trade Uncertainty Rattles Global Stock Markets | Open Interest 2/23/2026 Get a jump start on the US trading day with Matt Miller and Dani Burger on 'Bloomberg Open Interest.' Trade uncertainty rattles markets again as President Trump moves forward…

thehindu.com - Reuters - India's drug regulator inspected 90% of cough syrup makers, found lapses, official says
India's drug regulator inspected 90% of cough syrup makers, found lapses, official says
The Hindu

India's drug regulator has inspected nearly 90% of ​the country's cough syrup makers and found compliance lapses, its ⁠chief said on Monday (January 23, 2026), amid heightened scrutiny after India-made syrups were linked to the deaths…

zerohedge.com - Tyler Durden - Futures Slide As Renewed Tariff Turmoil Shakes Global Markets
Futures Slide As Renewed Tariff Turmoil Shakes Global Markets
Zero Hedge

Stock futures slumped after Trump's weekend tariff tantrum added uncertainty to American trade policy and was another blow to bullish outlooks for 2026. The Supreme Court's tariff ruling means a big source of fiscal revenue from 2025 may have to be…

globenewswire.com - Artios Pharma - Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
GlobeNewswire

U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated HER2-negative breast cancer Artios is launching a global randomized Phase 2 study to evaluate ART6043 in patients with…

theguardian.com - Julia Kollewe - Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded 'obsolete'
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded 'obsolete'
The Guardian

The owner of Wegovy and Ozempic has suffered a significant setback, as its highly anticipated new weight-loss treatment was labelled “obsolete” after disappointing clinical trials. Novo Nordisk's shares fell sharply on Monday after…

seekingalpha.com - Edmund Ingham - Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued (AXSM)
Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued (AXSM)
Seeking Alpha

Axsome Therapeutics, Inc. delivered 66% full-year 2025 revenue growth to $638.5M, driven by Auvelity and Sunosi, but remains loss-making. Despite a robust pipeline and upcoming catalysts, I downgrade AXSM to Hold due to valuation risks and…

thehill.com - Rachel Frazin - Kennedy doubles down on defense of Trump glyphosate order amid MAHA backlash
Kennedy doubles down on defense of Trump glyphosate order amid MAHA backlash
The Hill

Health and Human Services Secretary Robert F. Kennedy Jr. is doubling down on his defense of President Trump's executive order boosting a controversial pesticide, which drew fury from members of the Make America Health Again (MAHA) movement. MAHA…

swissinfo.ch - swissinfo.ch - Uri: Franz Weber Foundation feels 'vindicated' in marina project
Uri: Franz Weber Foundation feels 'vindicated' in marina project
www.swissinfo.ch

The Federal Office for Spatial Development has clearly stated that the project with an artificial harbour would “seriously impair” the protected landscape on Lake Uri and is not eligible for approval, the press release stated. Around…

irishtimes.com - Jack Power - European Parliament pauses work ratifying EU-US tariff deal, amid fresh uncertainty
European Parliament pauses work ratifying EU-US tariff deal, amid fresh uncertainty
The Irish Times

Work to remove long-standing tariffs on American industrial goods has been paused by the European Parliament, while Brussels waits to see exactly how US President Donald Trump's plans to rework his tariff agenda. The commitment to remove mostly…

fool.com - Adria Cimino - 3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds
The Motley Fool

The weight loss drug market has been one key focus for investors in recent years. This is because demand has been incredibly high, driving blockbuster revenue for companies making such products -- here, I'm talking about pharma giants Eli Lilly and…

cnbc.com - Kai Nicol-Schwarz - UK companies seek deeper ties with Europe as Trump tariffs fuel uncertainty, business groups say
UK companies seek deeper ties with Europe as Trump tariffs fuel uncertainty, business groups say
CNBC

British companies are seeking stronger trade ties with Europe, business groups told CNBC, as tariff uncertainty continues. U.S. President Donald Trump unveiled a sweeping 15% tariff on all imports over the weekend, after the Supreme Court struck…

Receive a Daily briefing on Pharma Industry News

Get Started